Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) PT at $11.75

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $11.40.

A number of research firms have recently issued reports on VRCA. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating and issued a $12.00 target price on shares of Verrica Pharmaceuticals in a research report on Thursday, October 3rd. Royal Bank of Canada reduced their price target on Verrica Pharmaceuticals from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Friday, October 4th. Finally, TD Cowen dropped their target price on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday.

Verrica Pharmaceuticals Price Performance

Shares of VRCA stock opened at $1.51 on Monday. The company has a market capitalization of $64.05 million, a P/E ratio of -0.86 and a beta of 1.45. The company has a debt-to-equity ratio of 29.58, a current ratio of 2.36 and a quick ratio of 2.23. Verrica Pharmaceuticals has a one year low of $1.04 and a one year high of $11.41. The company’s 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $5.53.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its earnings results on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $4.70 million. As a group, equities analysts anticipate that Verrica Pharmaceuticals will post -1.58 EPS for the current year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in VRCA. Simplify Asset Management Inc. bought a new position in Verrica Pharmaceuticals during the 2nd quarter worth about $2,041,000. Renaissance Technologies LLC acquired a new position in shares of Verrica Pharmaceuticals in the second quarter valued at about $332,000. Quest Partners LLC bought a new position in Verrica Pharmaceuticals during the 2nd quarter worth $50,000. Rhumbline Advisers increased its stake in Verrica Pharmaceuticals by 20.4% in the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after acquiring an additional 4,514 shares during the last quarter. Finally, Key Financial Inc bought a new position in Verrica Pharmaceuticals in the second quarter valued at about $69,000. 42.45% of the stock is owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.